OOIR: Observatory of International Research

Papers

(The TQCC of Biochimica et Biophysica Acta-Reviews on Cancer is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Fibrosis and cancer: A strained relationship	316
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting	177
Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer	174
Cholesterol metabolism: New functions and therapeutic approaches in cancer	164
Advances in clinical immunotherapy for gastric cancer	147
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter	137
Altered glycosylation in cancer: A promising target for biomarkers and therapeutics	124
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer	119
Non-coding RNAs and potential therapeutic targeting in cancer	109
Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.	107
Progress and challenges of immunotherapy in triple-negative breast cancer	102
Targeting tumor microenvironment in ovarian cancer: Premise and promise	102
The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential	99
Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives	96
Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside	94
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy	92
Caspase-8: The double-edged sword	90
Cholesterol and beyond - The role of the mevalonate pathway in cancer biology	84
The emerging role of paraptosis in tumor cell biology: Perspectives for cancer prevention and therapy with natural compounds	79
HER2-targeted therapies in gastric cancer	76
Understanding and advancement in gold nanoparticle targeted photothermal therapy of cancer	75
Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy	74
Targeting tumor-associated macrophages for cancer immunotherapy	65
The role of N6-methyladenosine mRNA in the tumor microenvironment	65
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal	65

Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types	63
Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics	59
Tumor-associated neutrophils and neutrophil-targeted cancer therapies	56
Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors	56
Metabolic reprogramming in renal cancer: Events of a metabolic disease	55
Genomic instability, inflammatory signaling and response to cancer immunotherapy	55
The RNA m6A writer METTL14 in cancers: Roles, structures, and applications	54
New insights on sorafenib resistance in liver cancer with correlation of individualized therapy	53
Pharmacological significance of the non-canonical NF-κB pathway in tumorigenesis	52
Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer	51
The clinical relevance of gene expression based prognostic signatures in colorectal cancer	51
PTEN in osteosarcoma: Recent advances and the therapeutic potential	51
Immunotherapy for advanced hepatocellular carcinoma, where are we?	50
Long non-coding RNAs and cancer metastasis: Molecular basis and therapeutic implications	49
Communication in tiny packages: Exosomes as means of tumor-stroma communication	49
LOXL2 in cancer: regulation, downstream effectors and novel roles	48
Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions	48
Combinatorial therapy in tumor microenvironment: Where do we stand?	48
The emerging role of miRNA clusters in breast cancer progression	46
HOX genes function in Breast Cancer development	46
Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression	46
DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer	44
Non-mitotic functions of polo-like kinases in cancer cells	44
Targeting Bcl-2 for cancer therapy	44
SOS GEFs in health and disease	42
The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer	42
Classification of extrachromosomal circular DNA with a focus on the role of extrachromosomal DNA (ecDNA) in tumor heterogeneity and progression	41
CCR7 as a therapeutic target in Cancer	41
The emerging roles of exosomes in anti-cancer drug resistance and tumor progression: An insight towards tumor-microenvironment interaction	41
Nerve input to tumours: Pathophysiological consequences of a dynamic relationship	40
Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy	39
Cyclin-dependent kinases in DNA damage response	39
SOX9: An emerging driving factor from cancer progression to drug resistance	39
Cancer regeneration: Polyploid cells are the key drivers of tumor progression	36
Enzyme-based autophagy in anti-neoplastic management: From molecular mechanisms to clinical therapeutics	36
Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma	36
Bacteria as a double-action sword in cancer	36
Resistin: An inflammatory cytokine with multi-faceted roles in cancer	35
E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers	35
Mitochondria: The metabolic switch of cellular oncogenic transformation	35
HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential	35
Emerging roles of HSF1 in cancer: Cellular and molecular episodes	35
Cross talk between autophagy and oncogenic signaling pathways and implications for cancer therapy	35
Human MYC G-quadruplex: From discovery to a cancer therapeutic target	35
Pre-clinical tumor models of primary brain tumors: Challenges and opportunities	34
Organoid model: A new hope for pancreatic cancer treatment?	34
Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore	34
The role of CAF derived exosomal microRNAs in the tumour microenvironment of melanoma	34
Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer	34
The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma	33

GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment	33
Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions	33
Recent advances in organoid development and applications in disease modeling	33
MYBL2 amplification in breast cancer: Molecular mechanisms and therapeutic potential	33
The outstanding antitumor capacity of CD4+ T helper lymphocytes	32
MCM family in gastrointestinal cancer and other malignancies: From functional characterization to clinical implication	32
Metabolic tricks of cancer cells	32
RUNX1 and cancer	31
Delivery routes matter: Safety and efficacy of intratumoral immunotherapy	31
Role of tyrosine phosphorylation in modulating cancer cell metabolism	31
Closing the translation gap: AI applications in digital pathology	30
New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies	30
Drug resistance in colorectal cancer: An epigenetic overview	30
Modeling pancreatic cancer in mice for experimental therapeutics	30
HOX genes and the NF-κB pathway: A convergence of developmental biology, inflammation and cancer biology	30
Role of gut microbiota in epigenetic regulation of colorectal Cancer	29
Nucleic acid nanotechnology for cancer treatment	29
The progress of immune checkpoint therapy in primary liver cancer	29
Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model	29
Odors and cancer: Current status and future directions	28
FOX transcription factor family in hepatocellular carcinoma	28
Pathogenesis and therapeutic strategy in platinum resistance lung cancer	28
A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors	28
Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer	28
A “hit-and-run” affair – A possible link for cancer progression in virally driven cancers	27
Metabolic heterogeneity in cancer: An overview and therapeutic implications	27
The multifaceted roles of gasdermins in cancer biology and oncologic therapies	27
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents	27
EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy	26
Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing	26
Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission	26
P53 in skin cancer: From a master player to a privileged target for prevention and therapy	26
DNA damage response inhibitors: An avenue for TNBC treatment	25
Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?	25
Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy	25
Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance	25
Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy	25
Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer	24
The use of nanotechnology to combat liver cancer: Progress and perspectives	24
Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs	24
Epigenetic memory in development and disease: Unraveling the mechanism	24
EpCAM cellular functions in adhesion and migration, and potential impact on invasion: A critical review	24
Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology	24
CRISPR screen in mechanism and target discovery for cancer immunotherapy	24
Mitochondrial dynamics, a new therapeutic target for Triple Negative Breast Cancer	24
Exosomes: The protagonists in the tale of colorectal cancer?	24
Inhibiting homologous recombination by targeting RAD51 protein	24
Tumor draining lymph nodes, immune response, and radiotherapy: Towards a revisal of therapeutic principles	24
Colorectal cancer: Metabolic interactions reshape the tumor microenvironment	23
Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression	23
Platinum-based systematic therapy in triple-negative breast cancer	22
Gut mycobiome: A promising target for colorectal cancer	22
Small nucleolar RNA and its potential role in breast cancer – A comprehensive review	22
The evolution and ecology of benign tumors	22
Pericytes cross-talks within the tumor microenvironment	22
Technologies for targeting DNA methylation modifications: Basic mechanism and potential application in cancer	22
Mesenchymal stem cells in glioblastoma therapy and progression: How one cell does it all	22
Multifaceted roles of HSF1 in cell death: A state-of-the-art review	22
Immunomodulatory effects of ablation therapy on tumors: Potentials for combination with immunotherapy	22
New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab	21
Targeting EGFR in melanoma – The sea of possibilities to overcome drug resistance	21
Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression	21
Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients	21
Centrosome amplification in cancer and cancer-associated human diseases	21
Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer	21
The role of DNA damage and repair in liver cancer	21
Recent advances in understanding the molecular role of phosphoinositide-specific phospholipase C gamma 1 as an emerging onco-driver and novel therapeutic target in human carcinogenesis	21
Super-enhancers: A new frontier for glioma treatment	20
βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies	20
Peptides that immunoactivate the tumor microenvironment	20
Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies	20
PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway	20
Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression	20
Protein phosphatase 1 in tumorigenesis: is it worth a closer look?	20